Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS (REGN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Regeneron Pharmaceuticals : Announces Upcoming Investor Conference Presentation

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/18/2018 | 03:31pm CEST

TARRYTOWN, N.Y., May 18, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its management presentation at the Goldman Sachs 39th Annual Global Healthcare Conference at 8:40 a.m. Pacific Time (11:40 a.m. Eastern Time) on Tuesday, June 12, 2018.

The session may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events.cfm.  A replay of the webcast will be archived on the Company's website and will be available for 30 days.

About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:  


Investor Relations           

Corporate Communications

Manisha Narasimhan, Ph.D.                   

Hala Mirza

914.847.5126    

914.847.3422             

[email protected]

[email protected]

 

Cision View original content:http://www.prnewswire.com/news-releases/regeneron-announces-upcoming-investor-conference-presentation-300650631.html

SOURCE Regeneron Pharmaceuticals, Inc.


© PRNewswire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
05/25REGENERON PHARMACEUTICALS : Patent Issued for Angiopoietin-Based Interventions f..
AQ
05/25REGENERON PHARMACEUTICALS : and Sanofi Share First Positive Clinical Data for Ce..
AQ
05/24Kiniksa upsizes IPO, raises $152.6M
AQ
05/22REGENERON PHARMACEUTICALS : Positive Phase 3 Trial of DUPIXENT in Adolescents wi..
AQ
05/22REGENERON PHARMACEUTICALS : and Sanofi Share First Positive Clinical Data for Ce..
AQ
05/22REGENERON PHARMACEUTICALS : Announces Upcoming Investor Conference Presentation
AQ
05/21REGENERON PHARMACEUTICALS : New England Journal of Medicine Publishes Two Positi..
PU
05/21SANOFI : - First positive clinical data for cemiplimab in advanced non-small cel..
AQ
05/18REGENERON PHARMACEUTICALS : Announces Upcoming Investor Conference Presentation
PR
05/18REGENERON PHARMACEUTICALS : and Sanofi Share First Positive Clinical Data for Ce..
AQ
More news
News from SeekingAlpha
05/23Is Celgene's Stock A Buy The Dip Opportunity? 
05/21New England Journal of Medicine publishes on Dupixent Phase 3 trials 
05/21VALEANT PHARMACEUTICALS : Worth At Least $30 
05/18MeiraGTx Aims For $86 Million U.S. IPO 
05/17REGENERON UNKNOWN : Eylea Future Competition Effects